PRO MEDICUS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.9 AUD | +0.66% |
|
+5.80% | +12.62% |
| Apr. 02 | Pro Medicus Limited authorizes a Buyback Plan. | CI |
| Apr. 01 | Pro Medicus Limited announces an Equity Buyback for 10,442,488 shares, representing 10% of its issued share capital. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With an expected P/E ratio at 141.42 and 107.79 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +12.62% | 7.26B | C- | ||
| +4.46% | 32.45B | C | ||
| +21.71% | 3.84B | B- | ||
| -8.78% | 3.43B | C- | ||
| -24.45% | 1.31B | B | ||
| -35.53% | 1.11B | - | ||
| +2.79% | 919M | C | ||
| -24.21% | 856M | - | C+ | |
| -39.85% | 840M | - | ||
| -16.60% | 712M | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- PME Stock
- Ratings Pro Medicus Limited
